NCT07346547Not yet recruiting
REDCURE Registry for Chronic Kidney Disease (CKD) Anemia
Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 384 (estimated)
- First submitted
- 8 Jan 2026
- Start date
- 30 Jan 2026
- Primary completion date
- 30 Jan 2027
- Lead sponsor
- Nabiqasim Industries (Pvt) Ltd
- Diseases
- Chronic kidney disease
- NCT number
- NCT07346547
What you commit to
- Study type: Observational
- Planned participants: 384
- From 30 Jan 2026 to the primary completion date, 30 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
Other
- Acute Kidney Injury (AKI) without underlying chronicity
- Refusal or inability to provide consent
- Current enrollment in an interventional trial that restricts real-world data collection
- Life expectancy \< 3 months, where follow-up is not feasible
- Known contraindications to Daprodustat as per local prescribing information
Who the study is looking for
- Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
- Patients on hemodialysis (HD) or peritoneal dialysis (PD)
- Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.